Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed, indicating an update to the page’s revision history.SummaryDifference0.0%

- Check24 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. The new version is now displayed.SummaryDifference0.0%

- Check52 days agoChange DetectedAdded Revision: v3.4.2 and removed the funding-related notice (Revision: v3.4.1); these changes do not modify the study details, eligibility criteria, or outcomes presented on the page.SummaryDifference0.4%

- Check60 days agoChange DetectedAdded a government funding/operating status notice and updated the page revision tag from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check67 days agoChange DetectedUI/metadata updates were made: added Show glossary, Results First Posted, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0. Removed items include Results First Posted (Estimated), Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.3%

- Check81 days agoChange DetectedRevision tag updated: v3.3.4 added and v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.